Clinical nutrition最新文献

{"title":"Poly- and perfluoroalkyl substances (PFAS) in the first 1000 days reduce linear growth, lean body mass and bone mineral density at age 3 years","authors":"Inge A.L.P. van Beijsterveldt ,&nbsp;Demi J. Dorrepaal ,&nbsp;Bertrand D. van Zelst ,&nbsp;Sjoerd A.A. van den Berg ,&nbsp;Anita C.S. Hokken-Koelega","doi":"10.1016/j.clnu.2025.05.017","DOIUrl":"10.1016/j.clnu.2025.05.017","url":null,"abstract":"<div><h3>Background and aims</h3><div>Poly- and perfluoroalkyl substances (PFAS) are non-degradable, man-made-chemicals. They are considered to be ‘Endocrine Disrupting Chemicals’ (EDCs), a group of chemicals which interfere with endocrine processes and cause adverse effects on perinatal, neurodevelopmental, metabolic and reproductive outcomes. Especially when exposure occurs during susceptible periods of development, such as early life. Infants who had exclusive breastfeeding (EBF) for at least 3 months, have persistently 3-times higher PFAS plasma levels compared to infants who had exclusive formula feeding (EFF) during the ‘<em>first 1000 days’</em> of life. However their effects on growth and body composition outcomes are lacking. We investigated the associations between early life plasma PFAS levels and growth, body composition and metabolic outcomes at age 3 years. Secondly, we studied if the influence of PFAS was different for EBF- and EFF-children, in order to examine if PFAS exposure through human milk diminishes the known health benefits of breastfeeding.</div></div><div><h3>Methods</h3><div>In 237 healthy term-born infants (99 EBF, 57 EFF and 81 mix), included in Sophia Pluto birth cohort, we determined anthropometrics, blood pressure, body composition and total body bone mineral density (BMD) by Dual-energy-X-ray Absorptiometry (DXA) at age 3 years. The plasma levels of 5 PFAS were determined by liquid-chromatography-electrospray-ionization-tandem-mass-spectrometry (LC-ESI-MS/MS) in samples collected at age 3 months and 2 years. We studied the associations between plasma PFAS levels and outcomes at age 3 years using multiple regression models, corrected for confounders, such as feeding practices in early life.</div></div><div><h3>Results</h3><div>Higher PFAS levels at age 3 months and 2 years were associated with less linear growth from birth until age 3 years (B: −0.068, p = 0.004 and B:-0.105, p &lt; 0.001) and with shorter height SDS (B: −0.063, p = 0.010 and B:-0.099,p &lt; 0.001) at age 3 years. Additionally, higher PFAS levels at age 2 years were associated with lower lean body mass (LBM) SDS and lower BMD_TotalBody SDS at age 3 years (B: −0.064, p = 0.003 and B:-0.075, p = 0.018, respectively). In contrast, exclusive breastfeeding for at least 3 months was positively associated with the same outcomes (B: 0.204, p = 0.010 and B: 0.274, p = 0.019, respectively).</div></div><div><h3>Conclusions</h3><div>Higher plasma PFAS levels in ‘<em>the first 1000 days’</em> of life were negatively associated with height, LBM and BMD SDS at age 3 years, while exclusive breastfeeding during the first 3 months of life was positively associated with these outcomes. This suggest that early life plasma PFAS levels could jeopardize breastfeeding's known health benefits, which warrants further research.</div></div>","PeriodicalId":10517,"journal":{"name":"Clinical nutrition","volume":"50 ","pages":"Pages 175-182"},"PeriodicalIF":6.6,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144168809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Omega-3 polyunsaturated fatty acids and nonalcoholic fatty liver disease in adults: A meta-analysis of randomized controlled trials","authors":"Su Jin Kim ,&nbsp;Su Hwan Cho ,&nbsp;Jae Moon Yun","doi":"10.1016/j.clnu.2025.05.013","DOIUrl":"10.1016/j.clnu.2025.05.013","url":null,"abstract":"<div><h3>Background and aims</h3><div>Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver disease worldwide. Previous meta-analyses investigating the effects of omega-3 polyunsaturated fatty acids (ω-3 PUFA) on NAFLD have reported inconsistent findings. This study aimed to evaluate the efficacy and adverse (AEs) of ω-3 PUFA in adults with NAFLD.</div></div><div><h3>Methods</h3><div>PubMed, MEDLINE, Embase, and Cochrane Library databases were searched for randomized controlled trials (RCTs) published until November 30, 2024. Data were pooled, and meta-analyses were conducted using a random-effects model. The Cochrane Collaboration's Risk of Bias 2.0 tool was used. Subgroup analyses of aspartate aminotransferase (AST) and alanine transaminase (ALT) levels were performed based on treatment duration, dosage, metabolic dysfunction-associated steatotic liver disease (MASLD), nonalcoholic steatohepatitis (NASH), age, and sex.</div></div><div><h3>Results</h3><div>Twenty RCTs with 1615 participants were included. The overall risk of bias was 5/20 low risk (25 %), 4/20 high risk (20 %) and 11/20 some concerns (55 %). ω-3 PUFA supplementation significantly improved gamma-glutamyltransferase (GGT) (WMD = −5.38 IU/L, 95 % CI: −9.16 to −1.61) and hepatic steatosis assessed by ultrasonography (US) (OR = 3.83, 95 % CI: 1.03 to 14.27) compared with the control group, although publication bias was observed. No significant effects were observed on AST, ALT, or hepatic fat measured by magnetic resonance spectroscopy (MRS) or MRI-proton density fat fraction (MRI-PDFF), hepatic stiffness, or histology. ω-3 PUFA group was more likely to experience overall AEs compared with the control group. However, the number of RCTs reporting sufficient information was limited.</div></div><div><h3>Conclusions</h3><div>ω-3 PUFA supplementation may improve GGT levels and hepatic steatosis assessed by US. However, substantial heterogeneity and the limited number of ultrasound-based studies necessitate further well-designed RCTs. Moreover, careful monitoring of AEs during supplementation was necessary, highlighting the need for long-term safety data.</div></div>","PeriodicalId":10517,"journal":{"name":"Clinical nutrition","volume":"50 ","pages":"Pages 164-174"},"PeriodicalIF":6.6,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144154390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integration of metabolomics and machine learning for precise management and prevention of cardiometabolic risk in Asians","authors":"Xinyan Bi ,&nbsp;Lijuan Sun ,&nbsp;Michelle Ting Yun Yeo ,&nbsp;Ker Ming Seaw ,&nbsp;Melvin Khee Shing Leow","doi":"10.1016/j.clnu.2025.05.011","DOIUrl":"10.1016/j.clnu.2025.05.011","url":null,"abstract":"<div><div>Rapid changes in dietary patterns have led to a rise in cardiometabolic diseases (CMDs) worldwide, highlighting the urgent need for effective dietary strategies to address the health issues. Compared to Caucasians, Asians are more susceptible to CMDs. Understanding the complex factors driving this increased susceptibility is essential for developing targeted interventions and preventive measures for Asian populations. Metabolomics plays a key role in identifying specific metabolic markers and pathways associated with CMDs, providing insights into disease mechanisms and helping to create individualized risk profiles. However, metabolomics faces several challenges, including difficulties in interpreting results across diverse ethnic groups, limitations in study design, variability in analytical platforms, and inconsistencies in data processing methods. Overcoming these challenges requires the adoption of advanced technologies, standardized approaches, and integration of multi-omics data to maximize the utility of metabolomics in clinical settings. As the volume and complexity of metabolomic data continue to increase, machine learning (ML) algorithms have become essential for effective data integration, interpretation, and knowledge extraction. Advanced ML techniques, such as deep learning and network analysis, can reveal hidden patterns, relationships, and metabolic pathways within large datasets, leading to deeper insights into biological systems and disease processes. By combining metabolomics and ML, we can facilitate early detection, enable personalized interventions, and support the development of targeted nutritional strategies, ultimately improving therapeutic outcomes and reducing the socioeconomic burden of CMDs in this region.</div></div>","PeriodicalId":10517,"journal":{"name":"Clinical nutrition","volume":"50 ","pages":"Pages 146-153"},"PeriodicalIF":6.6,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144131216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic β-carotene, magnesium, and zinc supplementation together with metformin attenuates diabetes-related complications in aged rats","authors":"Ramya Kateel ,&nbsp;Namita N. Kashyap ,&nbsp;Shivakumar K. Reddy ,&nbsp;Sahana Shetty ,&nbsp;Meena K. Kumari ,&nbsp;Sheetal D. Ullal ,&nbsp;Sadhana N. Holla ,&nbsp;Annayya Aroor ,&nbsp;Michael A. Hill ,&nbsp;Vijetha Shenoy Belle ,&nbsp;Krishnananda Prabhu ,&nbsp;Manjunath B. Joshi ,&nbsp;Dinesh Upadhya","doi":"10.1016/j.clnu.2025.05.004","DOIUrl":"10.1016/j.clnu.2025.05.004","url":null,"abstract":"<div><div>Aged type 2 diabetes mellitus (T2DM) patients are linked with lower serum levels of total antioxidant activity, magnesium and zinc, particularly under uncontrolled hyperglycemia. Uncontrolled oxidative stress is an established contributor to diabetic complications. Magnesium is a cofactor for ∼600 enzymes, while zinc is a part of ∼3000 human proteins, essential for intermediary metabolism. A multi-targeted approach combining β-carotene, Magnesium and Zinc (BMZ) with metformin or vitamin E, Magnesium and Zinc (EMZ) with metformin for daily use in aged rats with T2DM identified astonishing findings compared to metformin monotherapy. Over three months, compared to metformin monotherapy, BMZ with metformin provided excellent glycemic control, outstanding protection against potential neuropathy and sensorimotor coordination, maintained robust retinal integrity and provided significant control for diabetic nephropathy. Mechanistically, the significant improvement in BMZ with metformin in controlling retinopathy, nephropathy, and neuropathy are directly linked to (1) Increased glycemic control (antihyperglycemic effect), (2) increased insulin sensitivity as evidenced by reduced HOMA-IR levels, (3) reduced oxidative stress (4) increased antioxidant activity through increased glutathione levels and increased GSH/GSSG ratio, and (5) improved regulation of carbohydrate and lipid metabolism as evidenced by metabolomic data. This study provides robust and direct evidence to support the use of affordable, proven antioxidant and mineral combinations with metformin to reduce diabetes-related complications in aging.</div></div>","PeriodicalId":10517,"journal":{"name":"Clinical nutrition","volume":"50 ","pages":"Pages 183-197"},"PeriodicalIF":6.6,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144168808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dietary patterns and transition from normal cognition to mild cognitive impairment and its reversion: A longitudinal study of older adults","authors":"Xiaofu Du ,&nbsp;Bin Gao ,&nbsp;Jiangtao Zhang ,&nbsp;Jing Guo","doi":"10.1016/j.clnu.2025.05.010","DOIUrl":"10.1016/j.clnu.2025.05.010","url":null,"abstract":"<div><h3>Background</h3><div>The reversion from mild cognitive impairment (MCI) to normal cognition (NC) has received less attention than the progression to dementia. We aimed to estimate the MCI-to-NC reversion rate and examine dietary patterns associated with the cognitive transition among older adults.</div></div><div><h3>Methods</h3><div>Longitudinal data from 11,211 adults aged 65 years and older were analyzed. Four dietary patterns including plant-based diet index (PDI), simplified healthy eating index (SHEI), dietary diversity score (DDS), and the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) were assessed with the food frequency questionnaire. Cognitive function was quantified with the Mini-Mental State Examination. The multi-state Markov models were applied to estimate associations between each dietary pattern and transition of cognitive status with four states: NC, MCI, dementia, and death.</div></div><div><h3>Results</h3><div>Participants (mean [SD] age, 85.80 [11.13] years; 6211 women [55.40 %] and 5000 men [44.60 %]) were followed over a mean time of 4.76 (SD = 3.14) years. The rate of reversion from MCI to NC was 9.4 %. Hazard ratios (HRs, 95 % confidence interval [CI]) for the progression from NC to MCI were 0.87 (0.77–0.97), 0.81 (0.73–0.91), 0.95 (0.92–0.99), and 0.95 (0.92–0.99) for dietary patterns of healthful PDI (hPDI), SHEI, DDS, and MIND, respectively. Besides, a better adherence to hPDI (HR = 1.21, 95 % CI = 1.03 to 1.43) and SHEI (HR = 1.20, 95 % CI = 1.02 to 1.41) was associated with increased likelihoods to revert from MCI to NC.</div></div><div><h3>Conclusions</h3><div>Dietary patterns of hPDI, SHEI, DDS, and MIND were linked to decreased risks of NC-to-MCI progression, and hPDI and SHEI were associated with higher likelihoods of MCI-to-NC reversion in older adults. Interventional studies with dietary patterns were warranted to confirm our findings.</div></div>","PeriodicalId":10517,"journal":{"name":"Clinical nutrition","volume":"50 ","pages":"Pages 137-145"},"PeriodicalIF":6.6,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144124549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of multi-strain probiotics supplementation on body adiposity and metabolic profile in individuals with hypertension and overweight following an energy-restricted diet: A randomized clinical trial","authors":"Karine Scanci da Silva Pontes ,&nbsp;Marcella Rodrigues Guedes ,&nbsp;Priscila Guadagno de Souza ,&nbsp;Mario Fritsch Toros Neves ,&nbsp;Márcia Regina Simas Torres Klein","doi":"10.1016/j.clnu.2025.05.005","DOIUrl":"10.1016/j.clnu.2025.05.005","url":null,"abstract":"<div><h3>Background &amp; aims</h3><div>Recent evidence suggests that gut microbiota has a potential role in the pathophysiology of obesity and other cardiovascular disease (CVD) risk factors, including hypertension, dyslipidemia, and type 2 diabetes. However, clinical trials evaluating the effects of probiotics supplementation on these outcomes have found inconsistent results, probably due to the wide heterogeneity in trial designs. In addition, there is a lack of studies investigating whether probiotics can enhance the beneficial effects of caloric restriction in individuals with increased risk of CVD as individuals with hypertension and excess body adiposity. Thus, the aim of this study was to evaluate the effects of multi-strain probiotics supplementation on body adiposity, glycemic homeostasis, lipid profile, and serum adipokine levels in individuals with hypertension and excess body weight following an energy restricted diet.</div></div><div><h3>Methods</h3><div>A randomized, double-blind, placebo controlled clinical trial was conducted for 12 weeks. Were included 66 individuals aged between 40 and 65 years; both sexes; body mass index (BMI) ≥ 25 and &lt; 40 kg/m² and diagnosis of hypertension. Were excluded smokers; individuals using probiotics, prebiotics, symbiotics and antibiotics in the last 3 months; presenting diabetes, chronic kidney disease or liver failure; and pregnant and lactating women. Participants were allocated into 2 groups: group with supplementation of 8 probiotic strains in capsules (3 × 10¹⁰ CFU/day) or control group (placebo capsules). Both groups followed a low-calorie diet. Participants underwent anthropometric, body composition (dual-energy radiological absorptiometry) and biochemical (glucose metabolism, lipid profile, adiponectin, and leptin) evaluation at baseline and at the end of the study.</div></div><div><h3>Results</h3><div>After 12 weeks of intervention, the probiotics group presented: a) reduction of body weight, BMI, circumferences of waist, hip and neck and waist-to-height ratio; b) decrease in total fat mass (kg); and c) reduction of glycated hemoglobin (HbA1c). In the control group, it was observed: a) significant reduction in all anthropometric variables; b) significant reduction in total fat mass (kg and %), trunk fat mass (kg), visceral fat and load capacity index. In the comparison between groups, there was a higher decrease in HbA1c in the probiotics group (p &lt; 0.05).</div></div><div><h3>Conclusion</h3><div>Multi-strain probiotics supplementation associated with energy restriction in individuals with excess body weight and hypertension promoted a significant improvement in glucose homeostasis assessed by HbA1c. The clinical trial was registered at <span><span>www.ensaiosclinicos.gov.br</span><svg><path></path></svg></span>: RBR-7jw4ry.</div></div>","PeriodicalId":10517,"journal":{"name":"Clinical nutrition","volume":"50 ","pages":"Pages 117-127"},"PeriodicalIF":6.6,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144115071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oxidative stress markers and tissue iron overload after 12-months vitamin E supplementation for children with transfusion-dependent β-thalassemia on different iron chelators: A randomized placebo-controlled trial","authors":"Mohamed A. ElLaboudy ,&nbsp;Maha M. Saber ,&nbsp;Amira A. Adly ,&nbsp;Eman A. Ismail ,&nbsp;Fatma A. Ibrahim ,&nbsp;Omar M. Elalfy","doi":"10.1016/j.clnu.2025.05.003","DOIUrl":"10.1016/j.clnu.2025.05.003","url":null,"abstract":"<div><h3>Background</h3><div>Vitamin E is an anti-oxidant depleted in thalassemia as a result of iron overload.</div></div><div><h3>Aim</h3><div>We investigated the efficacy and safety of vitamin E as an adjuvant therapy to iron chelators in transfusion-dependent thalassemia patients in relation to tissue iron overload and examine its potential corrective value to oxidative stress markers including peroxiredoxin-2 (PRDX2).</div></div><div><h3>Methods</h3><div>This randomized prospective study included 180 pediatric patients with transfusion-dependent β-thalassemia who were equally divided into three groups to either receive desferrioxamine (DFO), deferiprone (DFP) or deferasirox (DFX). Patients in each group were further randomized to receive vitamin E supplementation (400 mg daily) or matching placebo. Patients were followed-up for 12 months with assessment of oxidative stress markers (malondialdehyde [MDA], reduced glutathione, superoxide dismutase, glutathione peroxidase and PRDX2), serum ferritin (SF), liver iron content (LIC) and cardiac T2∗ by magnetic resonance imaging. The primary endpoint was the change between groups from baseline to 12 months as regards LIC.</div></div><div><h3>Results</h3><div>After vitamin E therapy, transfusion index, SF and LIC were significantly decreased while hemoglobin and cardiac T2∗ were elevated compared with baseline levels or placebo group. MDA levels were decreased while the studied antioxidants were improved after vitamin E supplementation compared with baseline levels or placebo. DFX-treated patients had the highest hemoglobin level with the lowest SF, LIC and MDA levels compared with DFO or DFP subgroups.</div></div><div><h3>Conclusions</h3><div>Vitamin E is a safe adjuvant anti-oxidant therapy that potentiates the efficacy of DFX in reducing iron burden in transfusion-dependent β-thalassemia patients.</div><div>This trial was registered under ClinicalTrials.gov Identifier no. NCT06509581.</div></div>","PeriodicalId":10517,"journal":{"name":"Clinical nutrition","volume":"50 ","pages":"Pages 154-163"},"PeriodicalIF":6.6,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144134317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of Pappalysin-2 (PAPP-A2), a modulator of Insulin-like Growth Factor-1 pathway, as a potential marker of teduglutide efficacy in patients with short bowel syndrome","authors":"Brune de Dreuille ,&nbsp;Rémy Nicolle ,&nbsp;Jérôme Cros ,&nbsp;Dominique Cazals-Hatem ,&nbsp;Anaïs Chassac ,&nbsp;Nicolas Poté ,&nbsp;Johanne Le Beyec-Le Bihan ,&nbsp;André Bado ,&nbsp;Maude Le Gall ,&nbsp;Francisca Joly","doi":"10.1016/j.clnu.2025.05.006","DOIUrl":"10.1016/j.clnu.2025.05.006","url":null,"abstract":"<div><h3>Background</h3><div>Teduglutide, a glucagon-like peptide-2 (GLP-2) analog, is indicated to treat short bowel syndrome (SBS) since 2015. It has been shown to reduce parenteral support (PS) in SBS patients, although patients’ response is quite heterogeneous. The exact mechanisms of action of GLP-2 on intestinal cells are still poorly understood. The aim of this study was to explore the intestinal action of teduglutide to identify molecular mechanisms underlying response heterogeneity.</div></div><div><h3>Methods</h3><div>A retrospective study was conducted in 39 SBS patients treated with teduglutide for at least 6 months. Intestinal biopsy specimens collected before and after treatment initiation were selected and analyzed by RNA sequencing to identify genes differentially expressed and pathways regulated following teduglutide treatment.</div></div><div><h3>Results</h3><div>Of the 39 patients included in the study, 29 (74%) had a colon in continuity. The overall response to teduglutide was a reduction by 75% (interquartile range: 42–100) in PS volume. Among the genes differentially expressed in the small bowel during teduglutide treatment, the most significantly upregulated gene was <em>PAPPA2</em> (q-value &lt; 0.0001), encoding the metalloproteinase Pappalysin-2 (PAPPA-2) involved in Insulin-like Growth Factor (IGF) bioavailability. The best responders to teduglutide showed a lower <em>PAPPA2</em> expression at baseline (p &lt; 0.01). <em>PAPPA2</em> expression at baseline also correlated positively with the percentage of remnant colon (p &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>We identified a new stakeholder, PAPPA-2, known to modulate IGF bioavailability, as playing a possible role in GLP-2 mechanism of action in human with SBS. We showed by association the existence of a greater spontaneous intestinal adaptation in SBS patients with a colon in continuity that could reduce sensitivity to teduglutide. Additionally, we suggest that initial <em>PAPPA2</em> expression could serve as a predictive biomarker for teduglutide efficacy.</div></div>","PeriodicalId":10517,"journal":{"name":"Clinical nutrition","volume":"50 ","pages":"Pages 128-136"},"PeriodicalIF":6.6,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144125221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CiR-EIS alleviates metabolic dysfunction-associated steatohepatitis by modulating macrophage polarization involving the miR-548m/IGF1 axis","authors":"Xiaoman Chen ,&nbsp;Zhiping Wan ,&nbsp;Lili Wu ,&nbsp;Xiang Cai ,&nbsp;Hang Si ,&nbsp;Xiaoquan Liu ,&nbsp;Qiyi Zhao ,&nbsp;Fen Xu ,&nbsp;Hong Deng","doi":"10.1016/j.clnu.2025.05.009","DOIUrl":"10.1016/j.clnu.2025.05.009","url":null,"abstract":"<div><h3>Background &amp; aims</h3><div>Metabolic dysfunction-associated steatohepatitis (MASH) is a significant public health concern, with macrophage phenotypes implicated in its progression. Although extensive inflammation-suppressing circular RNA (ciR-EIS, formerly named as hsa_circ_0008882) has been implicated in inflammation regulation, its role in macrophage polarization within the context of MASH remains unexplored. This study aimed to clarify the effect of ciR-EIS on macrophage polarization in MASH.</div></div><div><h3>Methods</h3><div>Immunofluorescence-fluorescence in situ hybridization was used to evaluate the localization of ciR-EIS in human liver sections. THP-1-derived macrophages (TDMs) were utilized to study ciR-EIS functions in vitro<em>.</em> Flow cytometry and RT-qPCR were employed to evaluate macrophage polarization after transfection. Bodipy assay was used to measure lipid buildup in HepG2 cells. Immunohistochemistry was used to confirm liver insulin-like growth factor 1 (IGF1) expression. Retrospective clinical records were analyzed to examine the association between cir-EIS, IGF1, and MASH.</div></div><div><h3>Results</h3><div>CiR-EIS was downregulated in patients with MASH and colocalized with the macrophage marker CD68. CiR-EIS and mitochondrially encoded NADH dehydrogenase 5 (MT-ND5) were downregulated in M1 macrophages and upregulated in M2 macrophages. TDM-derived supernatants overexpressed ciR-EIS, significantly reducing HepG2 lipid deposition and inhibiting LX2 proliferation. Overexpression of ciR-EIS in TDMs significantly inhibited M1 macrophage markers CD86, interleukin-1 beta, and tumor necrosis factor-alpha while enhancing M2 macrophage markers CD163 and CD206. CiR-EIS regulated macrophage polarization in a manner involving the miR-548m/IGF1 axis. Serum IGF1 levels were positively correlated with ciR-EIS, and both of them were notably reduced in patients with MASH and inversely correlated with APRI and FIB-4 scores.</div></div><div><h3>Conclusions</h3><div>CiR-EIS regulates macrophage polarization in a manner involving the miR-548/IGF1 axis, thereby reducing hepatocyte lipid accumulation and stellate cell proliferation in MASH. It demonstrates potential as a diagnostic marker and therapeutic target for MASH.</div></div>","PeriodicalId":10517,"journal":{"name":"Clinical nutrition","volume":"50 ","pages":"Pages 104-116"},"PeriodicalIF":6.6,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144115072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “ESPEN practical short micronutrient guideline” [Clin Nutr 43 (2024) 825–857]","authors":"Mette M. Berger ,&nbsp;Alan Shenkin ,&nbsp;Oguzhan Sıtkı Dizdar ,&nbsp;Karin Amrein ,&nbsp;Marc Augsburger ,&nbsp;Hans-Konrad Biesalski ,&nbsp;Stephan C. Bischoff ,&nbsp;Michael P. Casaer ,&nbsp;Kursat Gundogan ,&nbsp;Hanna-Liis Lepp ,&nbsp;Angelique M.E. de Man ,&nbsp;Giovanna Muscogiuri ,&nbsp;Magdalena Pietka ,&nbsp;Loris Pironi ,&nbsp;Serge Rezzi ,&nbsp;Anna Schweinlin ,&nbsp;Cristina Cuerda","doi":"10.1016/j.clnu.2025.04.020","DOIUrl":"10.1016/j.clnu.2025.04.020","url":null,"abstract":"","PeriodicalId":10517,"journal":{"name":"Clinical nutrition","volume":"50 ","pages":"Page 75"},"PeriodicalIF":6.6,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143948992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}